Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Microbes Infect ; 11(2): 296-301, 2009 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-19110068

RESUMO

Bacillus Calmette-Guerin (BCG) is the only available vaccine against tuberculosis. The research for an improved vaccine is currently a very active field of investigation. In the present study, adjuvanticity effect of sterile sodium alginate on subcutaneous BCG vaccination in BALB/c mice was investigated. Mice were vaccinated subcutaneously with BCG plus alginate and the immune response and protective effect were compared to those of mice vaccinated with BCG alone by the same route. Proliferative and delayed-type hypersensitivity responses, IFN-gamma, specific anti-mycobacterium total IgG, IgG1 and IgG2a production were significantly higher in mice immunized subcutaneously with BCG plus alginate in comparison with results of mice immunized with BCG alone. Following systemic infection with BCG, mice vaccinated with BCG plus alginate had lower mean bacterial count compared to those vaccinated with BCG alone. The immune responses induced by subcutaneous administration of BCG plus alginate were significantly better than the responses induced by standard BCG vaccination.


Assuntos
Adjuvantes Imunológicos/farmacologia , Alginatos/farmacologia , Vacina BCG/imunologia , Adjuvantes Imunológicos/administração & dosagem , Alginatos/administração & dosagem , Animais , Anticorpos Antibacterianos/sangue , Vacina BCG/administração & dosagem , Contagem de Colônia Microbiana , Feminino , Ácido Glucurônico/administração & dosagem , Ácido Glucurônico/farmacologia , Ácidos Hexurônicos/administração & dosagem , Ácidos Hexurônicos/farmacologia , Hipersensibilidade Tardia , Imunoglobulina G/sangue , Injeções Subcutâneas , Interferon gama/metabolismo , Pulmão/microbiologia , Camundongos , Camundongos Endogâmicos BALB C , Tuberculose/prevenção & controle
2.
Drug Dev Ind Pharm ; 34(4): 390-402, 2008 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-18401781

RESUMO

The objective of this study was to obtain detailed information on the mechanism of drug release from mixed-film of pectin-chitosan/Eudragit RS. Pellets (710-840 microm in diameter) containing 60% theophylline and 40% microcrystalline cellulose were prepared by extrusion-spheronization method. Eudragit L100-55 enteric coating capsules included film-coated pellets of theophylline in theoretical coating weight gains of 10, 15, and 20%, with pectin-chitosan complex contents of 5, 10, 15, and 20% for each level of weight gain were prepared and subjected to in vitro drug release. Drug release from this system showed a bimodal release profile characteristic with the drug release enhancement, being triggered (burst release) in the colonic medium. The reason for burst drug release may be due to the enzymatic degradation of pectin via pectinolytic enzymes in the simulated colonic medium. The mechanism of drug release from each formulation was evaluated in the terms of zero-order, first-order, Higuchi and Korsmeyer-Peppas models. It was observed that none of the enteric coating capsules showed any drug release in the simulated gastric medium (phase I). The analysis of release profiles showed that zero-order kinetics was found as the better fitting model for all formulations in the simulated small intestine (phase II) and it could be due to the pectin-chitosan swelling and subsequent formation of aqueous channels. In the colonic medium (phase III), due to degradation of pectin and its leaching from the mixed-film, there was a modification in drug release kinetics from swelling-controlled at phase II to anomalous at phase III. It also was found that both zero-order and Higuchi models contributed in colonic drug release from most of the formulations.


Assuntos
Quitosana/química , Excipientes/química , Teofilina/química , Resinas Acrílicas/química , Cápsulas , Celulose/química , Química Farmacêutica , Preparações de Ação Retardada , Cinética , Modelos Biológicos , Pectinas/química , Tecnologia Farmacêutica
3.
Eur J Pharm Biopharm ; 67(1): 175-86, 2007 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-17346954

RESUMO

Polyelectrolyte complex (PEC) film between pectin as an anionic polyelectrolyte and chitosan as a cationic species was prepared by blending two polymer solutions at weight ratio of 2:1 and then solvent casting method. Besides pectin/chitosan PEC film, Eudragit RS, pectin/Eudragit RS and pectin/chitosan/Eudragit RS films were also prepared by aforementioned method. In mixed-film formulations, a fixed weight ratio of 1:5 of pectin or pectin/chitosan complex to Eudragit RS was used. Characterizations of pectin/chitosan interaction in solution were investigated by turbidity and viscosity measurement and in the solid state by Fourier transform infrared (FTIR) spectroscopy, wide angle X-ray diffraction (WAXRD) and thermogravimetric analysis (TGA). It was observed that the swelling profile of pectin/chitosan film was pH-dependent and its swelling ratio in phosphate buffer solution (PBS) pH 7.4 was about 2.5-fold higher than that of PBS pH 6.0. Formulation containing only pectin/chitosan could not protect free film from high swelling in the aqueous media, therefore, Eudragit RS as a water-insoluble polymer must be included in the mixed-film. The formation of PEC between pectin and chitosan resulted in a decrease in the crystallinity and thermal stability caused by the interactions between polyions. Drug permeation or diffusion studies were carried out using Plexiglas diffusion cell consisting of donor and acceptor compartments. Theophylline was selected as a model drug to measure permeability coefficient. Drug permeation through pectin/chitosan/Eudragit RS showed a sigmoidal pattern; whereas drug diffusion through pectin/Eudragit RS and Eudragit RS films followed a linear characteristic. The drug permeation through the ternary mixed-film showed a burst release upon exposure to PBS pH 6.0. This mixed-film formulation showed the potential for sigmoidal drug delivery with an initial, controllable slow release followed by a burst release immediately after the change in pH. The burst drug permeation might possibly be due to change in film's porosity.


Assuntos
Quitosana/química , Colo Sigmoide/metabolismo , Pectinas/química , Ácidos Polimetacrílicos/química , Sequência de Carboidratos , Química Farmacêutica , Difusão , Sistemas de Liberação de Medicamentos , Excipientes , Espectroscopia de Ressonância Magnética , Membranas Artificiais , Microscopia Eletrônica de Varredura , Dados de Sequência Molecular , Peso Molecular , Nefelometria e Turbidimetria , Espectroscopia de Infravermelho com Transformada de Fourier , Termogravimetria , Viscosidade , Difração de Raios X
4.
Iran J Immunol ; 3(3): 114-20, 2006 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-18698120

RESUMO

BACKGROUND: Different methods have been used for BCG vaccination. Alginate microspheres are useful in delivery of vaccines to the gastrointestinal tract by oral route. OBJECTIVE: To compare the immune response following oral microencapsulated and subcutaneous (SC) route administration of BCG vaccine in BALB/c mice. METHODS: Alginate microspheres were produced by an internal emulsification method within olive oil. Four groups of mice were studied, including two groups receiving oral gavages of microencapsulated and free BCG, one receiving SC injection of BCG, and a control group. T cell proliferation, specific anti-BCG total IgG, and IgG subclasses (IgG1 and IgG2a) were compared between groups 5 and 12 weeks after vaccination. RESULTS: The best result was achieved using oral microencapsulated form in comparison with oral BCG alone. CONCLUSION: Delivery of oral BCG with alginate microspheres is an effective way to induce immune response in BALB/c mice.

5.
Acta Pharm ; 56(3): 299-310, 2006 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-19831279

RESUMO

Pellets containing theophylline as a model drug and microcrystalline cellulose, in a ratio of 6:4, were prepared by the extrusion-spheronization method. The pellets were coated with Eudragit RS aqueous dispersions, containing various amounts of pectin-chitosan complex and different coating mass gains, using a fluidized-bed apparatus. Twelve formulations were developed, which differed in two factors: coating mass gain (10, 15 and 20%, m/m) and the amount of pectin-chitosan complex (5, 10, 15 and 20%, m/m). Drug release studies were conducted using the USP apparatus I (basket) in dissolution media, mimicking the conditions prevailing in the stomach, small intestine or colon. Studies have shown that the drug release rate and pattern were dependent on both of the two mentioned factors. Some formulations showed bimodal and burst drug release, being triggered in the colonic medium by the action of pectinolytic enzymes. In formulations with 15 or 20% (m/m) of coating mass gain and 5 or 10% (m/m) of pectin-chitosan, the burst drug release was eliminated and replaced by the lag phase of drug release. In the case of burst drug release in the colonic medium, formulations with 20% (m/m) of coating mass gain and 15 or 20% (m/m) of pectin-chitosan were found to be better than the other formulations. Studies on the surface SEMs of uncoated and coated pellets show that after coating, coated pellets become smoother and exposure to pectinolytic enzymes in the colonic medium may result in surface erosion.


Assuntos
Portadores de Fármacos/química , Sistemas de Liberação de Medicamentos , Teofilina/administração & dosagem , Resinas Acrílicas/química , Celulose/química , Química Farmacêutica , Quitosana/química , Excipientes/química , Trato Gastrointestinal/metabolismo , Microscopia Eletrônica de Varredura , Pectinas/química , Solubilidade , Teofilina/química
6.
Acta Pharm ; 54(4): 339-45, 2004 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-15634617

RESUMO

In previous studies, it was established that chitosan and its quaternized derivatives are potent enhancers of hydrophilic compounds absorption across intestinal epithelia. The aim of this study was to evaluate the application of a new quaternized chitosan, triethyl chitosan (TEC), in pharmaceutical approaches. TEC was synthesized by a one step process via a 2(2) factorial design to optimize the preparation conditions. In ex vivo experiments, everted rat colon sac was used to determine the effect of TEC on the penetration of hydrophilic compounds of different molecular masses (e.g., sodium fluorescein and brilliant blue) through colonic epithelia in comparison with chitosan at pH 7.4. These studies indicated a significant increase in absorption of sodium fluorescein and brilliant blue in the presence of TEC compared to chitosan. TEC bearing positive charge is able to interact with the tight junctions of colon epithelia and hence increase the permeation of sodium fluorescein and brilliant blue through the tight junctions. This investigation has shown that triethyl chitosan could be used as a penetration enhancer for poorly absorbable compounds in the colon drug delivery system.


Assuntos
Adjuvantes Farmacêuticos/química , Quitosana/análogos & derivados , Quitosana/química , Colo/metabolismo , Sistemas de Liberação de Medicamentos , Absorção Intestinal/fisiologia , Mucosa Intestinal/metabolismo , Adjuvantes Farmacêuticos/síntese química , Análise de Variância , Animais , Benzenossulfonatos/administração & dosagem , Benzenossulfonatos/farmacocinética , Transporte Biológico/efeitos dos fármacos , Transporte Biológico/fisiologia , Quitosana/síntese química , Colo/citologia , Fluoresceína/administração & dosagem , Fluoresceína/farmacocinética , Concentração de Íons de Hidrogênio , Técnicas In Vitro , Absorção Intestinal/efeitos dos fármacos , Peso Molecular , Ratos , Estatísticas não Paramétricas
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...